Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track CRIS with free AI briefings, catalyst countdowns, and dilution alerts.

CRIS · CURIS INC

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$5.1M Cash on Hand
1.6mo Cash Runway
Follow CRIS by email Get an email when CRIS reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about CRIS, unsubscribe in one click. Privacy

📣 What CRIS Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
chondrocyte-alginate gel suspension Vesicoureteral Reflux Phase 3 · NCT00004487 Unknown
Emavusertib (CA-4948) Myelodysplastic Syndromes Phase 2 · NCT05178342 Terminated
Zanubrutinib Chronic Lymphocytic Leukemia Phase 2 · NCT07271667 Recruiting
Fimepinostat (CUDC-907) Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including… Phase 2 · NCT02674750 Completed
Smac Mimetic GDC-0917 Lymphoma Phase 1 · NCT01908413 Terminated
HDAC/EGFR/HER2 Inhibitor CUDC-101 Head and Neck Cancer Phase 1 · NCT01384799 Completed
mFOLFOX7 Gastric Cancer Phase 1 · NCT05187182 Recruiting
Onvatilimab (CI-8993) Solid Tumor Phase 1 · NCT04475523 Completed
Cenopodlin (CA-170) Advanced Solid Tumors or Lymphomas Phase 1 · NCT02812875 Completed

Also used in these trials (approved or third-party drugs, not CRIS's own candidates): Venetoclax, Ibrutinib, Durvalumab, Gemcitabine Hydrochloride, Cisplatin, Nivolumab, Pembrolizumab, Rituximab, Trastuzumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

CRIS holds $5.1M in cash and short-term investments (as of Jun 30, 2026) and burns about $9.3M/quarter from operations, an estimated runway of 1.6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 70 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CRIS files for a raise →

👥 Who Owns CRIS

Insiders 4.2% Other 5%+ holders 6.5% Institutions 49% Public and other holders 40.3%
HolderTypeShares% of sharesAs of
Stonepine Capital Management, LLC Institution (13G, 5%+) 4,025,992 42.32% 2026-03-17
Thomas A. Satterfield, Jr. 5%+ holder (13G) 616,565 6.48% 2026-09-30
Armistice Capital, LLC Institution (13G, 5%+) 372,000 3.91% 2026-09-30
Nantahala Capital Management, LLC Institution (13G, 5%+) 258,739 2.72% 2026-09-30
James E Dentzer
President & CEO, Director · +970,089 options
Insider 148,730 1.56% 2026-03-20
Diantha Duvall
CFO · +422,283 options
Insider 77,707 0.82% 2026-03-20
Jonathan B. Zung
CDO · +423,986 options
Insider 66,667 0.70% 2026-03-20
Ahmed MD Hamdy
CMO · +400,001 options
Insider 66,667 0.70% 2026-03-20
Marc Rubin
Director · +101,201 options
Insider 28,108 0.30% 2026-03-20
Kenneth I Kaitin
Director · +21,200 options
Insider 11,407 0.12% 2026-03-31

Share count 9,512,232 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full CRIS picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CRIS and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.